Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”).
asserted
minds → commit → September
The voting results for each matter presented at the Meeting are set out below.
asserted
results → present → Meeting
The Company is also pleased to announce that, effective October 1, 2026, the Company’s legal name will be changed from “Cybin Inc.” to “Helus Pharma Inc.”.
asserted
name → announce → Inc.
The legal name change follows the Company’s adoption of the business name “Helus Pharma” on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage discovery and development company to a commercial-ready pharmaceutical company.
asserted
change → follow → company
Voting results are set out below:
2. Number of Directors
The special resolution to set the number of directors of Helus at eight was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting.
asserted
who → set → Meeting
Voting results are set out below:
asserted
results → set → ?
3. Name Change
The special resolution to change the name of the Company from “Cybin Inc.” to “Helus Pharma Inc.” or such other name as may be approved by the directors, was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting.
uncertain
who → change → Meeting
Voting results are set out below:
4. Election of Directors
Each of the nominees for election as director listed in Helus’s management information circular dated August 18, 2026 were elected as directors of Helus for the ensuing year or until their successors are elected or appointed.
asserted
successors → set → year
Voting results are set out below:
asserted
results → set → ?
About Helus Pharma
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity.
asserted
that → operate → neuroplasticity
The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
asserted
who → intend → depression
Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health.
asserted
that → work → health
Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder.
asserted
that → develop → disorder
Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
asserted
Pharma → have → NSAs
The Company operates in Canada, the United States, the United Kingdom, and Ireland.
asserted
Company → operate → Canada
Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature.
asserted
statements → relate → nature
Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.
uncertain
results → look → statements
These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations.
uncertain
statements → identify → may
Forward-looking statements in this news release include statements regarding the Company’s plans to transform from a clinical stage discovery and development company to a commercial-ready pharmaceutical company; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
asserted
statements → look → conditions
Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made.
asserted
statements → look → time
Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements.
uncertain
results → differ → statements
Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026 and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov.
uncertain
which → include → www.sec.gov
Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended.
uncertain
results → look → statements
Readers should not place undue reliance on the forward-looking statements and information contained in this news release.
asserted
Readers → place → release
The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
asserted
they → assume → law
The Company makes no medical, treatment or health benefit claims about Company’s proposed products.
uncertain
Company → make → products
The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds.
uncertain
Administration → evaluate → psilocin
The efficacy of such products has not been confirmed by approved research.
asserted
efficacy → confirm → research
There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition.
asserted
use → be → disease
Rigorous scientific research and clinical trials are needed.
asserted
research → need → ?
If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Company’s performance and operations.
uncertain
it → obtain → performance
Neither Cboe Canada nor the Nasdaq Global Market stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
asserted
Canada → approve → contents
The Aporia
